Introduction {#sec1-1}
============

Ankfy1, a membrane-bound protein, was first reported in 1999 (Ito et al., 1999). Ankfy1 has a molecular weight of approximately 130 kDa in both humans and mice, as detected by western blotting (Ito et al., 1999; Kuriyama et al., 2000). Ankfy1 does not have a typical transmembrane hydrophobic domain (Ito et al., 1999), but consists of a coiled-coil structure and a BTB/POZ domain at the N-terminal, multiple ankyrin repeats in the middle, and a FYVE-finger motif at the C-terminal (Ito et al., 1999; Kuriyama et al., 2000).

Ankfy1 has several names including ANKHZN (Ito et al., 1999) and Rabakyrin-5 (Schnatwinkel et al., 2004) and is widely expressed in multiple tissues during development and in adults (Ito et al., 1999; Kuriyama et al., 2000). Functionally, Ankfy1 is involved in different types of endocytosis, especially in macropinocytosis (Schnatwinkel et al., 2004). Ankfy1 can be found in large vacuolar structures associated with macropinocytosis through direct binding with Rab5. Overexpression of Ankfy1 can increase macropinocytosis while knockdown suppresses the process (Schnatwinkel et al., 2004). Ankfy1 is also found in early endosomes, and as shown by the limited effect of knockdown experiments, has a minor role in early endosome fusion (Schnatwinkel et al., 2004). Another study found that Ankfy1 plays marginal roles in endosome-to-Golgi retrieval and biosynthetic transport, as it is localized in the retromer *via* association with EH Domain Containing 1 (EHD1) and vacuolar protein sorting 26 (Vps26) (Zhang et al., 2012). In summary, there are few studies on Ankfy1 and all to date have been carried out *in vitro*. Based on these few studies, our current understanding indicates that Ankfy1 plays minor roles in endocytosis/vesicle shuffling.

From our previous genome-wide study in the developing mouse brain (Gray et al., 2004), we found Ankfy1 to be of significant interest. Ankfy1 displayed an interesting expression pattern during early development, with specific expression in the ventricular zone of the central nervous system (CNS), suggesting Ankfy1 functions within neural stem cells (NSCs)/precursor cells. Based on this observation, we developed Ankfy1 knockout (K/O) mice to carry out detailed studies on its function in neural development.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

The chimera mouse was ordered from the Mutant Mouse Resource & Research Center (MMRRC, UC Davis, CA, USA), where a gene-trap embryonic stem cell (ESC) line against Ankfy1 had already been generated. C57/BL6 and Balb/C inbred mice were purchased from Charles River Laboratories (MA, USA). The mice were housed in the Animal Facility Center of the Dana-Farber Cancer Institute (Boston, MA, USA) and Wuhan University (Wuhan, China). All animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publications No. 8023, revised 1978) and were approved by the Institutional Animal Care and Use Committee at the Dana-Farber Cancer Institute and Wuhan University.

*In situ* hybridization {#sec2-2}
-----------------------

The Ankfy1 probe was made by reverse transcription-polymerase chain reaction (PCR) from an embryonic day 13.5 (E13.5) mouse embryo. The primer sequences were 5′-CAC AAG TTT GTC TTG GCC GC and 3′-GGT CTA ATG GGT CTC CTG GG. The PCR product was 741 bp in size and cloned into a pSport1 plasmid. *In situ* hybridization was performed as previously described (Fu et al., 2009).

Cell culture {#sec2-3}
------------

### Neural stem cell culture {#sec3-1}

Mouse NSCs were isolated from the cortex of embryonic (E14) CD-1 mice (SJA Lab Animal, China). The mouse cortices were dissected out and transferred into a 15-mL tube containing cold phosphate buffered saline (PBS). The tissues were triturated with a pipette to make single-cell suspension and passed through a 70 μm cell strainer (Falcon, USA). After centrifugation at 800 r/min (TDL-40B, Anke, Shanghai, China) for 5 minutes, the cells were resuspended in Dulbecco\'s Modified Eagle Medium (DMEM)/F12 (Invitrogen, Carlsbad, CA, USA) containing L-glutamine (Sigma, St. Louis, MO, USA), B27 and N2 supplements (Invitrogen), 20 ng/mL epidermal growth factor, and 20 ng/mL fibroblast growth factor (Invitrogen). Cells were then seeded at a density of 2 × 105 cells/mL on 6-well plates coated with poly 2-hydroxyethylmethacrylate (Sigma). Cells were passaged every 5--8 days, depending on their growth, by mechanical dissociation. For differentiation, cells were dissociated and resuspended in DMEM/F12 containing L-glutamine and B27 and N2 supplements, then seeded on 24-well plates containing cover slips coated with poly-L-ornithine (15 mg/L; Sigma) at 1 × 104 cells/cm^2^. For immunostaining, NSCs were allowed to differentiate for 5 days.

### Mixed glial cell culture {#sec3-2}

Cortices from neonatal mouse (P1--2) were digested with Accumax (Chemicon, Santa Cruz, CA, USA) for 10 minutes at 37°C. Cortices were triturated and passed through a 70-μm cell strainer (Falcon, USA) to form a single-cell suspension. After centrifugation at 1,000 r/min for 5 minutes, the cells were suspended in DMEM/F12 + 10 % fetal bovine serum (Hyclone, Logan, UT, USA). When the cultured cell mixture reached 65--75 % confluence, the culture medium was replaced with DMEM/F12 + 15 % B104 cell-conditioned medium + 1% N2 supplement + 5 mg/L insulin (Sigma, USA) (modified oligodendrocyte progenitor cell \[OPC\] growth-medium). The modified OPC growth-medium was replaced daily. On day 7 after incubation with modified OPC growth-medium, mixed glial cells were used for immunostaining.

Immunofluorescence staining {#sec2-4}
---------------------------

The immunofluorescence procedure was performed as previously described (Fu et al., 2009), and conducted in E13.5 and E18.5 spinal cords of Ankfy1 null and littermate control mice. Briefly, the slides were washed three times with PBS, 10 minutes each. Afterwards, slides were blocked by 5 % normal goat serum for 1 hour. After blocking, primary antibodies were added and incubated at 4°C overnight. Slides were then washed in PBS three times, 10 minutes each, followed by incubation with appropriate secondary antibodies (Jackson ImmunoResearch, PA, USA) in PBS for 1 hour. The slides were washed three more times in PBS. Pictures were taken using a Nikon Eclipse Ni fluorescent microscope (Nikon, Tokyo, Japan).

The antibodies used in this study included: anti-Olig2 (1:10,000, from Dr. Charles Stiles\' lab, DFCI, Boston, MA, USA), anti-glutamine synthetase (1:500; MAB302, Chemicon), anti-NeuN (1:200; MAB377, Chemicon), anti-glast (1:4,000; AB1782, Chemicon), anti-Nkx2.2 (1:5; 74.5A5, Hybridoma Bank), anti-Sox9 (1:100; Ab5535, Chemicon), anti-glial fibrillary acidic protein (GFAP)-cy3 (1:200; C9205, Sigma), anti-Tuj1 (1:400; PRB-435P-100, Covance), anti-NG2 (1:50; Dr. Stallup\'s Lab, Burnham Institute for Medical Research, Cancer Research Center, La Jolla, CA, USA), anti-Sox10 (1:10; Dr. Anderson\'s Lab, Caltech, Pasadena, CA, USA), anti-Ankfy1 (B-6) (1:100; SC393353, Santa Cruz Biotechnology), and anti-Ankfy1 (1:100; 24890-I-AP, Proteintech, Rosemont, IL, USA).

Whole mouse necropsy {#sec2-5}
--------------------

Whole mouse necropsy (overall histological examination) was performed at the DF/HCC Rodent Histopathology Core in Harvard Medical School (USA) with four Ankfy1 null mice and two heterozygotes.

Results {#sec1-3}
=======

Ankfy1 expression matched neural precursor markers {#sec2-6}
--------------------------------------------------

In an earlier study, we performed genome-wide transcription factor screening during neural development (Gray et al., 2004). Since Ankfy1 protein contains a Zinc-finger motif, which could serve as a DNA-binding motif in many proteins, it was included in this study. Initial screening revealed that Ankfy1 was specifically expressed in the ventricular zone during early development; whilst a follow-up study highlighted its interesting expression patterns during neural development (**[Figure 1](#F1){ref-type="fig"}**). In the spinal cord during neuronal development (E11.5), Ankfy1 was highly expressed in the ventral part of the ventricular zone, where NSCs/neuronal precursors are located. Two days later at E13.5, Ankfy1 had restricted expression in the ventral ventricular zone. At this time, the spinal cord starts gliogenesis, therefore the majority of cells in the ventricular zone are glial precursors. Simultaneously, Ankfy1 was also specifically expressed in the ventricular zone in the hindbrain and midbrain, but not in the forebrain. Later on, Ankfy1 was expressed in the migrating neural/glial progenitors which radiated out from the ventricular zone into the parenchyma (**[Figure 1B](#F1){ref-type="fig"}**, from E15.5--P5). This expression pattern, especially in the developing spinal cord, matched that of glial progenitor markers (like Sox9), suggesting that Ankfy1 may play functional roles in NSCs and/or glial development.

![*In situ* hybridization showing expression patterns of Ankfy1 mRNA in the developing murine CNS.\
Ankfy1 expression in (A) embryonic day 13.5 (E13.5) mouse brain; (B) mouse spinal cord from E11.5 to postnatal day 5 (P5).](NRR-11-1804-g002){#F1}

Double staining experiments on cultured neural cells confirmed that Ankfy1 was expressed in glial progenitors (**[Figure 2](#F2){ref-type="fig"}**). In mixed glia cell cultures, Ankfy1 was expressed in NG2-positive glial progenitors (**[Figure 2B](#F2){ref-type="fig"}**). More than 95% NG2-immunoreactive cells were also positive for Ankfy1 and newly differentiated neural cells continued to express Ankfy1. However, NG2 levels were lower than those in the progenitor cells (**Figure [2A](#F2){ref-type="fig"}**, **[C](#F2){ref-type="fig"}**, **[D](#F2){ref-type="fig"}**). After NSCs were differentiated for 5 days *in vitro*, Ankfy1 was found to be expressed at low levels in different neural cell types, such as astrocytes (GFAP+ cells; **[Figure 2A](#F2){ref-type="fig"}**), neurons (Tuj1+ cells; **[Figure 2C](#F2){ref-type="fig"}**) and oligodendrocytes (Sox10+ cells; **[Figure 2D](#F2){ref-type="fig"}**). Since there are no previous studies of Ankfy1 in the nervous system, we investigated the function of this protein using a transgenic animal approach.

![Ankfy1 expression in different cell types; predominantly neural precursors in the central nervous system (fluorescent microscopy).\
Ankfy1 expression in (A) GFAP-immunoreactive cells (red), (B) NG2-immunoreactive cells (red), (C) Tuj1-immunoreactive cells (red), and (D) Sox10-immunoreactive cells. Ankfy1 was labeled with green fluorescence by double-immunolabeling. Arrows highlight double-immunoreactive cells. Arrowhead in B shows two Ankfy1^+^/NG2^+^ cells soon after dividing. The cells in A and B are mixed glial cultures, while C and D are differentiated NSCs after 5 days in differentiation media (without mitogens). Scale bars: 100 μm.](NRR-11-1804-g003){#F2}

Development of Ankfy1 null mice {#sec2-7}
-------------------------------

The chimera mouse was sourced and the colony raised in our animal facility. The gene-trap vector was inserted into intron 4, which is approximately 6 kb in length. Genomic PCR was performed to determine the exact insertion point. Heterozygote genomic DNA was used as the template DNA for PCR. The 3′-primer was chosen according to the sequence on the gene trap vector from bases 157--177. A series of 5′-primers were chosen based on the sequence of intron 4 at intervals of about 500 bases (starting positions 512, 1102, 1610, 2139, 2618, 3059, 3623, 4091, 4643, 5088, and 5611; **[Table 1](#T1){ref-type="table"}**). Only the first three 5′-primers produced PCR products (**[Figure 3A](#F3){ref-type="fig"}**). The PCR products with the 5′-primer at position 512, 1102 and 1610 were approximately 1.7 kb, 1.1 kb, and 0.6 kb, respectively (**[Figure 3A](#F3){ref-type="fig"}**). The PCR results consistently showed that the insertion site was around position 2000 in intron 4. The PCR results were sent for sequencing and the insertion site was determined at position 2067 (**[Figure 3B](#F3){ref-type="fig"}**). Once the insertion site was located, PCR primers were designed for genotyping the wild-type (WT) allele of Ankfy1 in the gene-trapped mice.

###### 

Sequences of the primers used to locate the insertion site of the gene-trap vector in the transgenic mouse genome

![](NRR-11-1804-g004)

![Sequential PCR and DNA sequencing results determined the insertion site of the gene-trap vector.\
(A) Sequential PCR results. Lanes 1--11 show PCR results with the 5′-primer at positions 512, 1102, 1610, 2139, 2618, 3059, 3623, 4091, 4643, 5088, and 5611 on the sequence of Ankfy1 intron 4, respectively. The first three lanes show PCR products at sizes approximately 1.6 kb, 1.1 kb, and 600 bp, respectively. (B) The sequencing results of the PCR product from lane 3 in A (transgene) was aligned with the sequences of Ankfy1 intron 4 (intron 4) and the gene-trap vector (vector). The number 2066 marks the position on the sequence of Ankfy1 intron 4.](NRR-11-1804-g005){#F3}

Ankfy1 null mice showed no phenotype change during development and in adults {#sec2-8}
----------------------------------------------------------------------------

Ankfy1 homozygotes were generated from hetero-heterozygote mating. However, the knockout (K/O) mice looked identical to the WT littermates and were viable and fertile with no obvious defects.

Since Ankfy1 is specifically expressed in NSCs/precursor cells, we carefully monitored neural development of the Ankfy1 null mice. At E13.5, the homozygote embryos were comparable in size to their WT littermates, with no differences in overall morphology. Simultaneously, we determined the expression of several precursor markers on the developing spinal cord, such as Glast, a radial glial marker, and Sox9, a glial precursor marker. There were no differences in gene expression patterns between the K/O and WT mice (**[Figure 4A](#F4){ref-type="fig"}**). Because Ankfy1 was only expressed in the ventral part of the spinal ventricular zone, we assessed some ventral neuronal precursor markers, such as Olig2 (pMN marker, data not shown) and Nkx2.2 (p3 marker). There were no differences in gene expression patterns between the K/O and WT mice (**[Figure 4A](#F4){ref-type="fig"}**; data not shown).

![Expression patterns of several neural markers in the developing spinal cords of Ankfy1 null and control mice (immunofluorescence staining, fluorescent microscopy).\
(A) Expression patterns of markers for radial glia (Glast), P3 neuronal precursors (Nkx2.2), and glial precursors (Sox9) in embryonic day 13.5 (E13.5) spinal cords of Ankfy1 null (K/O) and wild-type (WT) control mice. (B) Expression patterns of markers for oligodendrocytes (Olig2), astrocytes (glutamine synthetase, GS), and neurons (NeuN) in E18.5 spinal cords of Ankfy1 null (K/O) and wild-type (WT) mice. Scale bars: 100 μm.](NRR-11-1804-g006){#F4}

Neural development was further investigated at developmental stage E18.5 (**[Figure 4B](#F4){ref-type="fig"}**) in Ankfy1 K/O mice. Similarly, the homozygous embryos at this later stage could not be distinguished from the WT littermates and there were no differences in expression patterns of NeuN, Olig2 and glutamine synthetase.

In adult mice, we found no gross defects in Ankfy1 K/O mice up to two-months-old. Furthermore, whole mouse necropsy showed that within all the major organs, neither the K/O nor heterozygote mice had any histological differences from WT mice (data not shown). One K/O mouse displayed some liver fibrosis, implying potential cirrhosis. However, this defect was not replicated in the other three K/O mice. In cases where the K/O mice were maintained beyond 2 months, no obvious defects were observed.

Genetic background determined Ankfy1 knockout mouse survival {#sec2-9}
------------------------------------------------------------

The transgenic mouse was derived from the 129P2/OlaHsd ESC line. The chimera mice were mated with the C57/B6 mice for ten generations to obtain a transgene on a pure C57/B6 genetic background. During this process, homozygous mice could not be generated at the Mendelian ratio (**[Table 2](#T2){ref-type="table"}**). There were always some degenerated embryos (as early as E11.5) inside the heterozygous mothers after hetero-heterozygote mating (**[Table 2](#T2){ref-type="table"}**). Furthermore, litter sizes following hetero-heterozygote breeding were smaller in comparison with the normal C57/B6 litter size (**[Table 2](#T2){ref-type="table"}**).

###### 

Genotypes of the Ankfy1 hetero-hetero mated offspring (from F1 to F6 backcrossing of C57/BL6 inbred)

![](NRR-11-1804-g007)

After backcrossing with C57/BL6 mice for six generations, we were unable to obtain K/O embryos or pups. We checked as early as E11.5 in all cases and before E11.5 (E9--E10) in some cases, and could not find any homozygous embryos. Consistently, some degenerated embryos were found inside the heterozygous mothers after hetero-heterozygote mating. We tried genotyping degenerated embryos and found some of them were homozygotes for the Ankfy1 transgene.

We then switched the genetic background to Balb/C inbred mice. Again, as the genetic background became increasingly Balb/C, especially after six generations, the occurrence of K/O mice was negligible.

Discussion {#sec1-4}
==========

Ankfy1 was selected from our genome-wide screening because of its specific expression in NSCs/precursor cells (Gray et al., 2004). The Ankfy1 expression patterns matched those of glial precursors. During early development stages (E11.5--13.5), Ankfy1 was specifically expressed in the ventral ventricular zone in the CNS, except in the forebrain. At later stages (E15.5--P5), Ankfy1-immunoreactive cells radiated out from the ventricular zone to the parenchyma. Double-staining confirmed its expression in glial precursors. From these data, we speculate that Ankfy1 may play important roles in NSCs and/or glial precursors.

Although only limited *in vitro* studies exist on Ankfy1, it is reported to be involved in different types of endocytosis (Schnatwinkel et al., 2004; Zhang et al., 2012). Furthermore, experiments suggest that it plays a minor role in macropinocytosis *via* its association with Rab5 (Schnatwinkel et al., 2004; Zhang et al., 2012). Knockdown of Ankfy1 can cause an approximately 50 % decrease in macropinocytosis, but almost no effects in other types of endocytosis (Schnatwinkel et al., 2004; Zhang et al., 2012).

Macropinocytosis is thought to be important for membrane-receptor internalization and receptor tyrosine kinase pathways (Schmees et al., 2012; Nehru et al., 2013). Although overexpression of Ankfy1 can activate platelet-derived growth factor receptor-beta (PDGFRβ)-dependent signaling pathways, knockdown experiments have shown only a small effect on this pathway (Schmees et al., 2012; Nehru et al., 2013). Many studies have shown that macropinocytosis is important for several developmental processes, such as axon growth, cone development (Bonanomi et al., 2008), neural crest cell development (Padmanabhan and Taneyhill, 2015), and epithelial morphogenesis (Fabrowski et al., 2013). Macropinocytosis likely affects these processes through plasma membrane recycling.

Because of the interesting expression pattern of Ankfy1 in neural development, we studied the function of Ankfy1 using a transgenic animal model. However, Ankfy1 K/O mice showed no obvious defects in the CNS during development and in adults. There were no detectable defects on NSCs/precursor cells or neuronal/glial cells. The K/O mice looked normal showing no difference from the WT littermates. A detailed histological examination revealed no histological defects in all major organs of the K/O mice at two-months-old. Overall, our data suggest that the function of Ankfy1 during neural development is negligible, despite its specific expression in NSCs/precursors.

Ankfy1 was not expressed in the ventricular zone of the murine forebrain during development. Furthermore, in adult mice, we did not detect expression of Ankfy1 in the subventricular zone of the forebrain, where adult NSCs/precursors are located. Consequently, it is unlikely that Ankfy1 plays functional roles in adult neurogenesis.

To our surprise, Ankfy1 heterozygote mothers were unable to produce homozygous offsprings when they had a highly homogeneous genetic background. The gene-trap ESC line 129P2/OlaHsd was injected into C57/BL6 host blastocysts to generate chimeras. After six generations of backcrossing with C57/BL6 or Balb/C inbred mice, homozygotes were clearly absent. A few degenerated embryos were routinely found in pregnant heterozygous mothers as early as E11.5 (the earliest time point assessed). Even with less of a homogeneous genetic background (F1--F6), degenerated embryos occasionally appeared in heterozygous mothers after hetero-heterozygote mating. Furthermore, homozygotes were produced at a rate less than 1/4, the standard Mendelian ratio, and the litter sizes were smaller. These data showed that Ankfy1 protein affects early embryonic development, with a penetration level determined by genetic background. In the mixed genetic background, penetration was only partial; while in the more homogeneous background, penetration was 100%.

This phenomenon is not uncommon, despite being seldom reported. For example, Olig1 knockout mice with a mixed background are viable and fertile, showing a normal phenotype with only very mild delay in myelin formation. This defect is quickly self-corrected during late development stages (Lu et al., 2002). However, in a highly homogeneous C57/BL6 genetic background, Olig1 mutant mice have a severe myelin deficit and die before the third week after birth (Xin et al., 2005). Studies on another neural protein, the Alzheimer\'s amyloid precursor protein, showed similar results. The transgene Tg (amyloid precursor protein 695) merely induces the formation of amyloid plaques in the brains of outbred mice. However, it is lethal in inbred FVB/N or C57/BL6 mice (Carlson et al., 1997).

In summary, the membrane protein Ankfy1 is specifically expressed in NSCs/precursors during development. Ankfy1 K/O mice with a mixed genetic background showed no obvious phenotypic changes, particularly in respect of neural developmental defects. However, Ankfy1 K/O was lethal in early embryonic development in highly homogenous genetic backgrounds, such as C57/BL6 or Balb/C. These findings indicate that Ankfy1 plays important roles in early embryonic development and this function is highly regulated by genetic background. Our findings also showed that genetic background could play important and even dominant roles in determining the phenotype of transgenic mice.
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